5 results about "Haemoglobin Suresnes" patented technology

The present disclosure relates to a staining reagent combination comprising a reagent A and a reagent B. The staining reagent combination is capable of simultaneously assessing total count of WBC, differential count of WBC and haemoglobin concentration from a biological sample in suspension form. The staining reagent combination is ideal for use in microfluidic platforms due to its high viscosity and lower volume required for measurement. The staining reagent combination is economical, non-toxic, has quick reaction and long working time.

The present disclosure provides in vitro methods for identifying the presence or absence of haemoglobin S (HbS) or haemoglobin C (HbC) in a blood sample, kits and devices thereof. The inventors have found that HbS shows a substantial decrease in absorption under deoxygenated conditions compared to oxygenated conditions. The inventors expect HbC to show a similar decrease in absorption under deoxygenated conditions compared to oxygenated conditions. The methods, kits and devices of the disclosure employ this decrease in absorption under deoxygenated conditions to identify the presence or absence of HbS or HbC in a blood sample. The methods, kits and devices of the present disclosure are simple, low cost, and provide a rapid way to identify the presence or absence of HbS or HbC in a blood sample in a point-of-care setting.

The purpose of the present invention is to provide a medicine that is for use in instances of cyanide poisoning, hydrogen sulfide poisoning, and azide poisoning, that does not cause side effects, and that has excellent quick-acting properties and a high antidote effect. Specifically, the present invention is a medicine that is for use in instances of cyanide poisoning, hydrogen sulfide poisoning, and azide poisoning, and that contains, as an active ingredient, at least one selected from the group consisting of hemeproteins capable of binding to a cyanide ion (CN-), a hydrogen sulfide ion (HS-), and an azide ion (N3 -), hemeprotein-containing substances capable of binding to CN-, HS-, and N3 -, and heme derivatives capable of binding to CN-, HS-, and N3. More specifically, the present invention is a medicine or pharmaceutical composition for treatment or prophylaxis of cyanide poisoning, hydrogen sulfide poisoning, and azide poisoning.

The present invention relates to a system for detecting diseases and providing healthcare services (100). The system (100) comprises of a plurality of handheld devices (102), a database (126) for storing data of patient and a software module (128). The handheld device (102) is configured to measure vital parameter of a patient's body through a plurality of sensors (110), wherein the plurality of sensor (110) includes a temperature sensor (112), a pulse oximeter sensor (114), a pulse sensor (116), a plurality of ECG leads (118), a blood pressure sensor (120). Additionally, the handheld device (102) may be interfaced to the glucometer and haemoglobin meter. The handheld device (102) is further configured to connect the user to a healthcare provider for consultation through a video call. Therefore, the present invention bridge the gap between rural patients and experienced medical professionals, thereby improving healthcare access for those in remote or underserved areas.

The present disclosure provides methods for determining optical absorbance of a blood sample, methods for identifying the presence or absence of sickle haemoglobin in a blood sample, kits and devices thereof The present methods comprise measuring a first absorbance of the blood sample under a deoxygenated condition at 420-440 nm and measuring a second absorbance of the blood sample under the deoxygenated condition at 541-570 nm. A ratio of the second absorbance to the first absorbance and a difference between the first absorbance and the second absorbance are calculated and employed to identify the presence or absence of sickle haemoglobin and determine the amount of sickle haemoglobin. The methods, kits and devices of the present disclosure are simple, low cost, and provide a rapid way to identify the presence or absence of and amount of sickle haemoglobin in a blood sample in a point-of-care setting.